Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients

Launched by SHANGHAI GENERAL HOSPITAL, CHINA · Aug 20, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how different types of pneumonia (both severe and mild) are affected by antimicrobial resistance (AMR), which is when germs no longer respond to medicines designed to kill them. Researchers want to understand the unique bacteria present in the lungs of pneumonia patients and how many of these bacteria have developed resistance to treatment. They will collect samples from patients to create a detailed map of the bacteria involved in pneumonia cases from 2019 to 2025. This information will help doctors make better decisions about diagnosing and treating pneumonia in the future.

To participate in this study, you need to have a confirmed diagnosis of either severe or mild pneumonia based on specific guidelines. Participants should also have leftover biological samples from their clinical examinations, such as swabs or fluid from their lungs. However, individuals whose samples may have been contaminated, or those with certain limitations on sample collection, will not be eligible. If you join the trial, you can expect to contribute to important research that could improve treatment options for pneumonia.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients clinically diagnosed as severe pneumonia and mild pneumonia are diagnosed according to the Guidelines for the diagnosis and Treatment of community-acquired pneumonia in Adults (2019 edition) formulated by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA), who meet 1 of the following major criteria or ≥3 minor criteria can be diagnosed. The diagnostic criteria for severe and mild pneumonia in children were adopted by the British Thoracic Society (BTS) in 2011.
• • Clinical examination was performed, and there was biospecimen (nasopharyngeal swab, oropharyngeal swab, bronchoalveolar lavage fluid, sputum, blood, hydrothorax, lung tissue) remaining in the clinical microbiological examination.
• Exclusion Criteria:
• • Patients whose biological samples may be contaminated;
• • Patients with alveolar lavage fluid or hydrothorax volume less than 200μl.